Study guide

5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment

Key Takeaways Explain This Topic AI

Recipient CMV IgG positivity is the principal reactivation risk after allogeneic HCT; donor/recipient serostatus, graft/platform, GVHD therapy and immune recovery refine risk.

CMV end-organ disease presents as pneumonitis, gastrointestinal disease, retinitis with a characteristic 'pizza-pie' fundoscopic appearance, or marrow/graft dysfunction, and blood DNAemia alone does not establish organ disease.

Letermovir prevents CMV infection/disease in indicated CMV-seropositive allogeneic recipients without treating established CMV disease. The current label supports prophylaxis through day 100 and through day 200 for patients at risk for late CMV.

CMV viral-load thresholds and treatment choices are assay-, center-, organ- and patient-specific. Ganciclovir/valganciclovir can suppress marrow; foscarnet and cidofovir can injure kidneys/electrolytes; maribavir has important interactions and is not recommended with ganciclovir/valganciclovir.

Last updated: September 2026

Viral Infections: CMV Reactivation, Letermovir, EBV/PTLD, Adenovirus & HHV-6 Encephalitis

Core Clinical Principle: Following allogeneic transplantation, profound suppression of donor-derived T-cell immunity permits latent double-stranded DNA herpesviruses and polyomaviruses to reactivate. Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and Human Herpesvirus-6 (HHV-6) can progress rapidly from asymptomatic viremia to catastrophic, life-threatening organ disease. Modern clinical management relies on risk-stratified primary prophylaxis (letermovir), routine quantitative molecular surveillance (real-time PCR), and preemptive antiviral intervention prior to irreversible tissue injury.

1. Cytomegalovirus (CMV): Pathophysiology, Risk Stratification & Organ Disease

CMV (Human Betaherpesvirus 5) establishes lifelong latency within myeloid progenitor cells and endothelial tissues following primary infection. In healthy individuals, robust CD4+ and CD8+ memory T cells keep viral replication suppressed. Post-transplant T-cell depletion, graft-versus-host disease (GVHD), and immunosuppressive medications (corticosteroids, calcineurin inhibitors) disable this control.

Pre-Transplant Serostatus Risk Stratification

Pre-transplant IgG serological testing of both Donor (D) and Recipient (R) defines the baseline risk category:

Serostatus Match Risk Category Clinical Characteristics & Reactivation Dynamics

D− / R+ Recipient reactivation risk The recipient harbors latent CMV; absence of donor CMV memory may influence risk and recovery, but platform and prophylaxis matter.

D+ / R+ Recipient reactivation risk The recipient harbors latent CMV; donor serostatus is one factor in immune recovery and donor selection.

D+ / R− Primary-infection risk The recipient lacks prior immunity; assess donor/product and transfusion/exposure prevention under the program plan.

D− / R− Lowest baseline transplant-related CMV risk Neither party has serologic evidence of prior CMV, but new infection remains possible; follow the transfusion and exposure-prevention policy.

CMV End-Organ Disease Presentations

CMV Pneumonitis:

Presentation: Fever, nonproductive cough, dyspnea and hypoxemia with interstitial or ground-glass imaging can occur, but these findings overlap with other infections and noninfectious lung injury.

Diagnostics: Bronchoscopy/BAL testing and, when feasible, cytology or tissue are interpreted with plasma viral load and clinical context. BAL PCR alone can reflect pulmonary shedding and is not automatically definitive disease.

CMV Gastrointestinal Disease (Enteritis / Colitis / Esophagitis):

Clinical Signs: Intractable nausea, vomiting, retrosternal pain (esophagitis), severe watery or bloody diarrhea, abdominal cramping, and mucosal ulcerations.

Diagnostic challenge: Distinguish it from acute GI GVHD, medication injury and other infection. Endoscopy with tissue histology/immunohistochemistry is often needed; blood DNAemia alone does not establish GI disease.

CMV Retinitis:

Presentation: Painless visual loss, floaters, flashing lights (photopsia), and scotomas. Fundoscopy reveals characteristic "pizza-pie" or "cottage cheese and ketchup" appearance (perivascular retinal hemorrhages and dense white retinal infiltrates).

Cytopenias and marrow/graft dysfunction:

CMV infection and myelosuppressive antiviral therapy can accompany or worsen cytopenias. Evaluate marrow, drugs, other infections, relapse and graft function rather than attributing unexplained counts to CMV alone.

2. CMV Prevention: Letermovir and Surveillance

Letermovir inhibits the CMV terminase complex and is used for prophylaxis—not treatment of established CMV disease—in indicated CMV-seropositive allogeneic HCT recipients. Start within the labeled post-HCT window and continue through day +100; continuation through day +200 is labeled for patients at risk for late CMV infection/disease. Follow age, weight, route, kidney/liver and product-specific instructions.

With cyclosporine, the adult letermovir dose is reduced from 480 mg to 240 mg daily. Letermovir can also increase tacrolimus exposure, so review interactions and monitor concentrations. Breakthrough DNAemia can occur; surveillance interval and action threshold depend on assay, center, donor/platform, immune therapy and clinical syndrome.

3. CMV DNAemia and Disease Treatment

A reproducible CMV viral-load rise is interpreted against assay, specimen, trend, serostatus, prophylaxis, immune risk and symptoms. Programs set their own preemptive threshold; one value such as 1,000 IU/mL is not universal. Suspected tissue-invasive disease may require organ-directed examination and biopsy while treatment begins when clinically necessary.

Antiviral Principal issue Nursing/pharmacy focus

Ganciclovir / valganciclovir Marrow suppression; valganciclovir also requires reliable GI absorption Adjust for renal function; trend counts and viral load; assess absorption and resistance if response is inadequate.

Foscarnet Nephrotoxicity, electrolyte wasting, seizures and genital irritation Verify renal-adjusted dose, pump/line compatibility and individualized hydration; trend creatinine, calcium, magnesium, potassium and phosphate without causing overload.

Cidofovir Substantial renal tubular toxicity and ocular effects Use only in a specialist plan with renal adjustment, hydration/probenecid when required, urinalysis and ocular/symptom monitoring.

Maribavir Dysgeusia and important drug interactions Used for label-defined post-transplant refractory CMV infection/disease; review immunosuppressant concentrations. It is not recommended with ganciclovir/valganciclovir because of antagonism at pUL97.

Choice and duration depend on marrow reserve, renal function, organ disease, prior exposure/resistance, route and interactions. Trend clinical and virologic response rather than treating until one memorized day.

Loading diagram... Risk-Directed Viral Surveillance and Management

4. Matching the Monitoring Plan to the CMV Agent

Every agent used against CMV carries a distinct toxicity signature, and the nursing monitoring plan is determined by which drug the patient is receiving rather than by the diagnosis.

Ganciclovir and valganciclovir are myelosuppressive. Follow the complete blood count closely, because falling neutrophils in a patient still establishing engraftment may force a change in agent rather than a change in dose.

Foscarnet is nephrotoxic and profoundly disturbs electrolytes, causing hypocalcemia, hypomagnesemia, hypokalemia, and phosphate abnormalities. Pre- and post-infusion hydration is part of the order, not an optional nursing addition, and symptomatic hypocalcemia can present as perioral tingling, cramping, tetany, or seizure.

Cidofovir is markedly nephrotoxic and is administered with saline hydration and probenecid under a specific protocol; a missed probenecid dose is a reportable deviation rather than a minor omission.

Letermovir , used for prevention, is comparatively well tolerated but interacts with calcineurin inhibitors, so tacrolimus or cyclosporine levels are monitored when it is started or stopped.

Maribavir , for refractory or resistant disease, has its own interaction profile and characteristic taste disturbance, which patients tolerate better when warned in advance.

The generalizable point is that "the patient is on CMV treatment" is not an adequate handoff. Name the agent, because the laboratory to watch changes with it.